Ignite Creation Date:
2025-12-24 @ 7:32 PM
Ignite Modification Date:
2026-03-06 @ 9:42 PM
Study NCT ID:
NCT02370303
Status:
COMPLETED
Last Update Posted:
2018-03-21
First Post:
2015-02-17
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
Sponsor:
Mayo Clinic
Organization:
Study Overview
Official Title:
A Pilot Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
Status:
COMPLETED
Status Verified Date:
2018-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to isolate and measure circulating tumor cells in the blood stream to advance detection of cancer and treatment monitoring. In this study, the investigators will utilize the novel technology for circulating tumor cell detection in order to evaluate their presence in patients with lung cancer.
Detailed Description:
The plan is to collect both blood and tumor samples from the patient's lung cancer in order to validate this technology in detecting circulating tumor cells. The investigators will also obtain a postoperative blood sample to see if there is a decrease in the overall circulating tumor cell measurement once the tumor has been surgically removed.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: